Several studies previously reported that the presence of detectable ctDNA was associated with poor survival in pancreatic cancer [52, 53] or that the presence of KRAS alterations in ctDNA was a poor prognostic marker for OS in advanced PDAC [52, 54, 55]. This evidence concerns the gene KRAS and pancreatic neoplasm.